In this Q&A we discuss the role of PARP inhibitors in cancer treatment, their role in triple-negative breast cancer patients and look forward to ongoing trials in this setting.
Triple-Negative Breast Cancer
A first-in-class antibody-drug conjugate (ADC) called IMMU-132, resulted in clinical activity, and was safe and tolerable among patients with heavily pretreated metastatic triple-negative breast cancer.
Researchers at the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center have identified the potential of a protein called CIB1 as a new drug target for patients with an aggressive form of breast cancer.
A recent study of a novel antibody-drug conjugate (ADC) in patients with refractory breast cancer may be the next generation of targeted therapy.
Targeted treatments for triple-negative breast cancers--which test negative for estrogen (ER), progesterone (PR), and HER2 receptors--have been nonexistent outside of clinical trials. The problem being, without a hormonal target or genetic driver, drug development for this cancer population is challenging--until now.
For women with triple-negative breast cancer (TNBC), adding bevacizumab (Avastin) to standard neoadjuvant chemotherapy was more beneficial for those diagnosed with basal-like tumors compared to those with nonbasal-like tumors. This data was presented at the 2014 San Antonio Breast Cancer Symposium (SABCS), held Dec. 9-13, 2014.
A study of triple-negative breast cancer patients found that adding bevacizumab to chemo resulted in higher pCR rates in those with basal-like disease.
The PD-1 inhibitor pembrolizumab showed activity and had an acceptable safety profile in heavily pretreated metastatic triple-negative breast cancer patients.